Clinical Psychopharmacology and Neuroscience Papers in Press available online.

Development of a Guideline for Antipsychotic-induced Hyperprolactinemia in Korea Using the ADAPTE Process
Hye Ri Kim 1, Sun Mi Kim 1,*, Won Sub Kang 2, Hong Jun Jeon 3, Seung-Ho Jang 4, Duk-In Jon 5, Jeongwan Hong 6, Jong-Hyun Jeong 7
1Department of Psychiatry, College of Medicine, Chung-Ang University, Seoul, Republic of Korea, 2Department of Psychiatry, College of Medicine, Kyung Hee University, Seoul, Republic of Korea, 3Department of Psychiatry, Konkuk University Medical Center, Konkuk University School of Medicine, Seoul, Republic of Korea, 4Department of Psychiatry, School of Medicine, Wonkwang University, Iksan, Republic of Korea, 5Department of Psychiatry, Hallym University Sacred Heart Hospital, Hallym University College of Medicine, Anyang, Republic of Korea, 6Department of Psychiatry, Iksan Hospital, Iksan, Republic of Korea, 7Department of Psychiatry, College of Medicine, The Catholic University of Korea, Seoul
Objective: To develop an evidence-based guideline for the diagnosis and treatment of antipsychotic-induced hyperprolactinemia by adapting existing high-quality clinical guidelines with a view to improve the clinical symptoms and long-term quality of life of patients by providing appropriate management.
Methods: This guideline was developed according to the ADAPTE methodology. The adaptation process included determining key health questions, systematically searching and screening guidelines, evaluating the quality and contents of these guidelines, deriving recommendations for key questions, and performing a peer review. The selection criteria for the guideline search were (1) evidence-based guidelines, (2) published within the last 5 years, and (3) written in English or Korean.
Results: After evaluating the quality and content, we finally selected three guidelines for adaptation. The final output of the development process was 25 recommendations for 10 key questions. We adopted the Agency for Health Research Quality methodology and presented the level of evidence from levels I to IV. In addition, we defined the recommendation grades from grade A (strongly recommended) to D (no recommendation) based on the level of evidence and clinical significance of the recommendation.
Conclusion: The development and dissemination of the adapted guideline is expected to increase the certainty of medical decision making and improve the quality of medical care. Further studies on the effectiveness and applicability of the developed guideline are necessary.
Accepted Manuscript [Submitted on 2022-03-22, Accepted on 2022-04-12]